Assessment of Glycated haemoglobin in Patient with Acute Coronary Syndromes and Its Correlation with long Term Outcomes .

Background:Acute coronary syndrome constitutes a major global health burden, significantly contributing to morbidity and mortality. While glycated haemoglobin (HbA1C) has emerged as a promising indicator of glycemic control, its prognostic value in patients experiencing ACS remains unclear.Aim of the Study:This study aims to investigate the association between glycated haemoglobin levels and long-term complications in patients with acute coronary syndrome, considering clinical, biochemical, and echocardiographic characteristics.Materials and Methods:The study included 200 patients admitted to the As-Salam PortSaid Cardiology department with acute coronary syndrome from January 2023 to June 2023. Patients were divided into two groups: those with complications and those without. Data were collected on clinical, biochemical, and echocardiographic factors, including glycated haemogolobin levels, ejection fraction, SYNTAX score, and complications. The predictive value of glycated ahaemoglobin was analyzed using receiver operating characteristic curve analysis.Results:Elevated glycated haemoglobin levels were significantly associated with complications especially rehospitalization . A glycated haemoglobin level of 7.5% was identified as a cutoff for predicting worse clinical outcomes. Multivariate analysis revealed hypertension and lower ejection fraction as independent risk factors for complications. Conclusion:Glycated haemoglobin is a promising biomarker for predicting complications in acute coronary syndrome patients. Although it was associated with long-term complications in univariate analysis, hypertension and lower ejection fraction were the primary independent risk factors for complications.